PRMT5 is overexpressed in a number of cancers including melanoma, multiple myeloma, glioblastoma, lung, gastric, prostate, ovarian, and colorectal cancers,6 and high expression of PRMT5 often correlates with poor patient prognosis.6 Here, PRMT5 is linked to melanoma.